Cargando…

Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland

INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted...

Descripción completa

Detalles Bibliográficos
Autores principales: Parczewski, Milosz, Witak-Jedra, Magdalena, Maciejewska, Katarzyna, Bociaga-Jasik, Monika, Skwara, Pawel, Garlicki, Aleksander, Grzeszczuk, Anna, Rogalska, Magdalena, Jankowska, Maria, Lemanska, Malgorzata, Hlebowicz, Maria, Baralkiewicz, Grazyna, Mozer-Lisewska, Iwona, Mazurek, Renata, Lojewski, Wladyslaw, Grabczewska, Edyta, Olczak, Anita, Jablonowska, Elzbieta, Rymer, Weronika, Szymczak, Aleksandra, Szetela, Bartosz, Gasiorowski, Jacek, Knysz, Brygida, Urbanska, Anna, Leszczyszyn-Pynka, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225244/
https://www.ncbi.nlm.nih.gov/pubmed/25397498
http://dx.doi.org/10.7448/IAS.17.4.19753
_version_ 1782343469367296000
author Parczewski, Milosz
Witak-Jedra, Magdalena
Maciejewska, Katarzyna
Bociaga-Jasik, Monika
Skwara, Pawel
Garlicki, Aleksander
Grzeszczuk, Anna
Rogalska, Magdalena
Jankowska, Maria
Lemanska, Malgorzata
Hlebowicz, Maria
Baralkiewicz, Grazyna
Mozer-Lisewska, Iwona
Mazurek, Renata
Lojewski, Wladyslaw
Grabczewska, Edyta
Olczak, Anita
Jablonowska, Elzbieta
Rymer, Weronika
Szymczak, Aleksandra
Szetela, Bartosz
Gasiorowski, Jacek
Knysz, Brygida
Urbanska, Anna
Leszczyszyn-Pynka, Magdalena
author_facet Parczewski, Milosz
Witak-Jedra, Magdalena
Maciejewska, Katarzyna
Bociaga-Jasik, Monika
Skwara, Pawel
Garlicki, Aleksander
Grzeszczuk, Anna
Rogalska, Magdalena
Jankowska, Maria
Lemanska, Malgorzata
Hlebowicz, Maria
Baralkiewicz, Grazyna
Mozer-Lisewska, Iwona
Mazurek, Renata
Lojewski, Wladyslaw
Grabczewska, Edyta
Olczak, Anita
Jablonowska, Elzbieta
Rymer, Weronika
Szymczak, Aleksandra
Szetela, Bartosz
Gasiorowski, Jacek
Knysz, Brygida
Urbanska, Anna
Leszczyszyn-Pynka, Magdalena
author_sort Parczewski, Milosz
collection PubMed
description INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted drug resistance associated mutations (tDRM) frequency trend over time are available from 2010. In this study, we analyze the temporal trends in the spread of tDRM from 2008 to 2013. MATERIALS AND METHODS: Partial pol sequences from 833 antiretroviral treatment-naive individuals of European descent (Polish origin) linked to care in 9 of 17 Polish HIV treatment centres were analyzed. Drug resistance interpretation was performed according to WHO surveillance recommendations, subtyping with REGA genotyping 2.0 tool. Time trends were examined for the frequency of t-DRM across subtypes and transmission groups using logistic regression (R statistical platform, v. 3.1.0). RESULTS: Frequency of tDRM proved stable over time, with mutation frequency change from 11.3% in 2008 to 8.3% in 2013 [OR: 0.91 (95% CI 0.80–1,05), p=0.202] (Figure 1a). Also, no significant differences over time were noted for the subtype B (decrease from 8.4% 2008 to 6.2% in 2013 [OR: 0.94 (95% CI 0.79–1.11), p=0.45] and across non-B variants [change from 22.6% 2008 to 23.1% in 2013, OR: 0.94 (95% CI 0.75–1.19), p=0.62]. When patient groups were stratified according to transmission route, in MSM there was a trend for a NNRTI t-DRM decrease (from 6.8% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.02), p=0.0655, slope −0.74%/year) (Figure 1b), related to the subtype B infected MSM (decrease from 7% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.03), p=0.0662, slope −0.75%/year). Overall tDRM frequency decrease was also noted for the heterosexually infected patients [from 17.6% 2008 to 10.3% in 2013, OR: 0.83 (95% CI 0.67–1.02, p=0.077, slope −2.041%/year)] but did not associate with drug class (Figure 1c). In IDUs, the trends in t-DRM frequency were not significant over time (change from 1.9% in 2008 to 0 in 2013 [OR:1.24 (95% CI 0.73–2.26), p=0.4)]. CONCLUSIONS: The frequency of t-DRM in Poland is generally stable over time. Decrease in the overall tDRM frequency in heterosexual infected cases and NNRTI resistance in subtype B infected MSM may be related to the higher treatment efficacy of current cART.
format Online
Article
Text
id pubmed-4225244
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-42252442014-11-12 Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland Parczewski, Milosz Witak-Jedra, Magdalena Maciejewska, Katarzyna Bociaga-Jasik, Monika Skwara, Pawel Garlicki, Aleksander Grzeszczuk, Anna Rogalska, Magdalena Jankowska, Maria Lemanska, Malgorzata Hlebowicz, Maria Baralkiewicz, Grazyna Mozer-Lisewska, Iwona Mazurek, Renata Lojewski, Wladyslaw Grabczewska, Edyta Olczak, Anita Jablonowska, Elzbieta Rymer, Weronika Szymczak, Aleksandra Szetela, Bartosz Gasiorowski, Jacek Knysz, Brygida Urbanska, Anna Leszczyszyn-Pynka, Magdalena J Int AIDS Soc Poster Sessions – Abstract P221 INTRODUCTION: In Poland, the HIV epidemic has shifted recently from being predominantly related to injection drug use (IDU) to being driven by transmissions among men-who-have-sex-with-men (MSM). The number of new HIV cases has increased in the recent years, while no current data on the transmitted drug resistance associated mutations (tDRM) frequency trend over time are available from 2010. In this study, we analyze the temporal trends in the spread of tDRM from 2008 to 2013. MATERIALS AND METHODS: Partial pol sequences from 833 antiretroviral treatment-naive individuals of European descent (Polish origin) linked to care in 9 of 17 Polish HIV treatment centres were analyzed. Drug resistance interpretation was performed according to WHO surveillance recommendations, subtyping with REGA genotyping 2.0 tool. Time trends were examined for the frequency of t-DRM across subtypes and transmission groups using logistic regression (R statistical platform, v. 3.1.0). RESULTS: Frequency of tDRM proved stable over time, with mutation frequency change from 11.3% in 2008 to 8.3% in 2013 [OR: 0.91 (95% CI 0.80–1,05), p=0.202] (Figure 1a). Also, no significant differences over time were noted for the subtype B (decrease from 8.4% 2008 to 6.2% in 2013 [OR: 0.94 (95% CI 0.79–1.11), p=0.45] and across non-B variants [change from 22.6% 2008 to 23.1% in 2013, OR: 0.94 (95% CI 0.75–1.19), p=0.62]. When patient groups were stratified according to transmission route, in MSM there was a trend for a NNRTI t-DRM decrease (from 6.8% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.02), p=0.0655, slope −0.74%/year) (Figure 1b), related to the subtype B infected MSM (decrease from 7% 2008 to 1% in 2013, OR: 0.61 (95% CI 0.34–1.03), p=0.0662, slope −0.75%/year). Overall tDRM frequency decrease was also noted for the heterosexually infected patients [from 17.6% 2008 to 10.3% in 2013, OR: 0.83 (95% CI 0.67–1.02, p=0.077, slope −2.041%/year)] but did not associate with drug class (Figure 1c). In IDUs, the trends in t-DRM frequency were not significant over time (change from 1.9% in 2008 to 0 in 2013 [OR:1.24 (95% CI 0.73–2.26), p=0.4)]. CONCLUSIONS: The frequency of t-DRM in Poland is generally stable over time. Decrease in the overall tDRM frequency in heterosexual infected cases and NNRTI resistance in subtype B infected MSM may be related to the higher treatment efficacy of current cART. International AIDS Society 2014-11-02 /pmc/articles/PMC4225244/ /pubmed/25397498 http://dx.doi.org/10.7448/IAS.17.4.19753 Text en © 2014 Parczewski M et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Sessions – Abstract P221
Parczewski, Milosz
Witak-Jedra, Magdalena
Maciejewska, Katarzyna
Bociaga-Jasik, Monika
Skwara, Pawel
Garlicki, Aleksander
Grzeszczuk, Anna
Rogalska, Magdalena
Jankowska, Maria
Lemanska, Malgorzata
Hlebowicz, Maria
Baralkiewicz, Grazyna
Mozer-Lisewska, Iwona
Mazurek, Renata
Lojewski, Wladyslaw
Grabczewska, Edyta
Olczak, Anita
Jablonowska, Elzbieta
Rymer, Weronika
Szymczak, Aleksandra
Szetela, Bartosz
Gasiorowski, Jacek
Knysz, Brygida
Urbanska, Anna
Leszczyszyn-Pynka, Magdalena
Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title_full Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title_fullStr Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title_full_unstemmed Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title_short Time trends in HIV-1 transmitted drug resistance mutation frequency in Poland
title_sort time trends in hiv-1 transmitted drug resistance mutation frequency in poland
topic Poster Sessions – Abstract P221
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225244/
https://www.ncbi.nlm.nih.gov/pubmed/25397498
http://dx.doi.org/10.7448/IAS.17.4.19753
work_keys_str_mv AT parczewskimilosz timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT witakjedramagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT maciejewskakatarzyna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT bociagajasikmonika timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT skwarapawel timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT garlickialeksander timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT grzeszczukanna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT rogalskamagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT jankowskamaria timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT lemanskamalgorzata timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT hlebowiczmaria timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT baralkiewiczgrazyna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT mozerlisewskaiwona timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT mazurekrenata timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT lojewskiwladyslaw timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT grabczewskaedyta timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT olczakanita timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT jablonowskaelzbieta timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT rymerweronika timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT szymczakaleksandra timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT szetelabartosz timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT gasiorowskijacek timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT knyszbrygida timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT urbanskaanna timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland
AT leszczyszynpynkamagdalena timetrendsinhiv1transmitteddrugresistancemutationfrequencyinpoland